BrainsWay Reports Strong Q1 2026 Results: Revenue Up 35%, Net Income Over 100%, Reaffirms Full-Year Guidance

summarizeSummary

BrainsWay reported strong Q1 2026 financial results with significant revenue and net income growth, alongside positive operational highlights and reaffirmed full-year guidance.

check_boxKey Events

• Strong Q1 2026 Financial Performance

  Revenue grew approximately 35% year-over-year to $15.5 million, and net income increased by over 100% year-over-year to $2.3 million. Adjusted EBITDA more than doubled to $2.8 million.

• Reaffirmed Full-Year 2026 Guidance

  The company reiterated its full-year 2026 financial guidance, expecting revenue of $66-$68 million and Adjusted EBITDA of $12-$14 million, indicating continued profitability and growth.

• Significant Operational Momentum

  Remaining performance obligations grew 25% year-over-year to $75 million, and a record 117 Deep TMS Systems were shipped, representing a 44% increase compared to the prior year.

• Pipeline Expansion and Payer Support

  BrainsWay secured the first insurer coverage for its accelerated SWIFT™ Deep TMS protocol and plans an FDA filing in Q2 2026 for PTSD symptoms in MDD patients, expanding its clinical pipeline.

auto_awesomeAnalysis

BrainsWay delivered robust first-quarter results, significantly exceeding prior-year performance with substantial revenue and net income growth. The company's operational momentum, evidenced by increased system shipments and remaining performance obligations, supports its reaffirmed positive full-year guidance. Strategic investments and an upcoming FDA filing for PTSD further strengthen the long-term growth outlook, indicating continued expansion in its core markets and pipeline.